Alexion Pharmaceuticals reports that the European Commission has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease … more
Separately, Alexion reports that five abstracts from the Phase 3 PREVENT study of SOLIRIS® (eculizumab) in neuromyelitis optica spectrum disorder have been accepted for presentation at the 35thCongress of the European Committee for Treatment and Research in Multiple Sclerosis in Stockholm, September 11 to 13, 2019. … more